Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 8 (20), 33953-33960

Genetic Association Between PSA-158G/A Polymorphism and the Susceptibility of Benign Prostatic Hyperplasia: A Meta-Analysis

Affiliations
Review

Genetic Association Between PSA-158G/A Polymorphism and the Susceptibility of Benign Prostatic Hyperplasia: A Meta-Analysis

Xin-Jun Su et al. Oncotarget.

Abstract

Inconsistency between reported findings on the association of prostate specific antigen (PSA) gene -158G/A polymorphism with benign prostatic hyperplasia (BPH) susceptibility need a meta-analysis to obtain a more accurate conclusion. A systematic search was conducted in electronic databases for the collection of eligible studies on PSA -158G/A polymorphism and BPH susceptibility. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were then calculated. 7 case-control studies with 758 cases and 752 controls were included into the present meta-analysis. The analysis results showed no significant relationship between PSA -158G/A polymorphism and BPH susceptibility in total analysis. Interestingly, after subgroup analyses based on ethnicity and source of control, the polymorphism reduced the susceptibility of BPH in Caucasian group (AA vs. GG: OR=0.47, 95% CI=0.25-0.89; allele A vs. allele G: OR=0.68, 95% CI=0.49-0.93), but it increased the disease susceptibility in Asian (AA vs. GG: OR=1.63, 95% CI=1.02-2.60; allele A vs. allele G: OR=1.37, 95% CI=1.03-1.83) and population-based (AA vs. GG: OR=2.39, 95% CI=1.07-5.38; allele A vs. allele G: OR=1.83, 95% CI=1.26-2.65) groups. PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.

Keywords: BPH; PSA; meta-analysis; polymorphism.

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1. Flow diagram of selecting eligible studies for the meta-analysis
Figure 2
Figure 2. Forest plot of BPH susceptibility associated with PSA -158G/A polymorphism under AA
vs. GG model after stratification analysis by ethnicity. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
Figure 3
Figure 3. Forest plot of BPH susceptibility associated with PSA -158G/A polymorphism under allele A
vs. allele G model after stratification analysis by source of control. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
Figure 4
Figure 4. Begg's funnel plot for publication bias under the model AA
vs. GG. Each point represents a separate study for the indicated association. Log(OR), natural logarithm of OR. Horizontal line, mean effect size.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Dobrek L, Thor PJ. Benign prostatic hyperplasia - progress in pathophysiology and management. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2015;39:263–270. - PubMed
    1. Kucerova R, Bienova M, Kral M, Bouchal J, Trtkova KS, Burdova A, Student V, Kolar Z. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer. Journal of the European Academy of Dermatology and Venereology. 2015;29:91–96. - PubMed
    1. Karatzas A, Tzortzis V, Giannatou E, Gravas S, Zachos I, Oeconomou A, Melekos M, Tsezou A. Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men. Molecular biology reports. 2013;40:6665–6669. - PubMed
    1. Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clinical interventions in aging. 2008;3:511–524. - PMC - PubMed
    1. Ray A, Morgan H, Wilkes A, Carter K, Carolan-Rees G. The urolift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A nice medical technology guidance. Applied health economics and health policy. 2016 - PMC - PubMed

Substances

Feedback